Reporting from ASCO 2023, Alex Herrera discusses the results from the SWOG study on nivolumab in advanced stage classic Hodgkin Lymphoma.
Abstract: LBA4 - SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL), presented by Alex Herrera.
The ESMO Educational Videos series features renowned experts in oncology sharing their knowledge on a variety of subjects. Full series here https://oncologypro.esmo.org/oncology-news/esmo-videos